Alphamab Oncology (HKG:9966)

Market Cap	8.08B -11.7%
Revenue (ttm)	630.11M -11.5%
Net Income	-126.79M
EPS	-0.13
Shares Out	968.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,958,000
Open	8.20
Previous Close	8.14
Day's Range	8.20 - 8.82
52-Week Range	6.23 - 15.75
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) tha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 498
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9966

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 20, 2026

Data Sources Report a data error